M. Sterckx

NEW DRUGS IN MEDICAL ONCOLOGY: NEW DIFFICULTIES TO DISTINGUISH DRUG-INDUCED SIDE EFFECTS FROM CANCER COMPLICATIONS: A CASE-REPORT

J. Machiels, Y. Humblet, E. Seront, 2011, Acta clinica Belgica.

Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.

G. Ossenkoppele, G. Verhoef, E. Morra, 2007 .

Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: A multicenter phase II study

G. Joos, J. Meerbeeck, D. Schallier, 2004 .

Imatinib use in chronic phase CML in clinical practice: the UNIC study

D. Marin, G. Ossenkoppele, G. Verhoef, 2008 .